Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04691570
PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Sponsor: Annexon, Inc.

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Official title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

7

Start Date

2021-11-10

Completion Date

2023-01-17

Last Updated

2026-06-30

Healthy Volunteers

No

Interventions

DRUG

ANX005

ANX005 is provided as a solution for IV infusion

Locations (4)

Investigational Site 01

Rochester, Minnesota, United States

Investigational Site 03

Melbourne, Australia

Investigational Site 04

Vienna, Austria

Investigational Site 02

Sofia, Bulgaria